Moran Wealth Management
CRSP icon

Moran Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Moran Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.1M Buy
37,903
+2,529
+7% +$136K 0.06% 316
2026
Q2 		$1.93M Buy
35,374
+10,072
+40% +$531K 0.05% 330
2026
Q1 		$1.2M Buy
25,302
+8,717
+53% +$460K 0.04% 345
2025
Q4 		$870K Sell
16,585
-5,112
-24% -$306K 0.03% 367
2025
Q3 		$1.41M Buy
21,697
+8,043
+59% +$462K 0.04% 311
2025
Q2 		$664K Buy
+13,654
New +$528K 0.02% 366

Other funds holding CRSP

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $8.04B AUM 33.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Moran Wealth Management's CRSP Position: Q3 2026 in Review

Moran Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 7.1% in Q3 2026, buying an estimated $136K and bringing the position to 37,903 shares worth $2.1M. The position accounts for 0.06% of the portfolio, ranked #316.

Moran Wealth Management first reported a position in CRSP in Q2 2025 and has held it in 6 quarters since. 388 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Moran Wealth Management held 37,903 shares of CRISPR Therapeutics worth $2.1M as of Q3 2026.
  • Moran Wealth Management bought 2,529 CRISPR Therapeutics shares in Q3 2026, an estimated $136K.
  • CRISPR Therapeutics made up 0.06% of Moran Wealth Management's portfolio in Q3 2026, its #316 holding.
  • Moran Wealth Management first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 388 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Moran Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.